Navigation Links
BioSpecifics Technologies Corp. Announces Launch of XIAPEX® by Pfizer for Treatment of Dupuytren's Contracture in Europe
Date:4/11/2011

LYNBROOK, N.Y., April 11, 2011 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced that it will receive a $2.5 million milestone payment as a result of the European launch and first commercial sale of XIAPEX (collagenase clostridium histolyticum ) in the United Kingdom, a major European market. Pfizer, Inc. (Pfizer), the EU licensee received approval from the European Medicines Agency (EMA) to market XIAPEX in Europe for the treatment of Dupuytren's contracture, a debilitating disorder resulting from excessive collagen deposition that causes contractures of the fingers. XIAPEX is the first injectable treatment to be approved in the EU for the treatment of this indication, which affects approximately 13% of the European population. (1)

"This approval is a significant milestone for XIAPEX and we look forward to its commercial success in this important market," commented Thomas L. Wegman, President of BioSpecifics. "We are confident that Pfizer's proven marketing and commercialization capabilities will aid in the success of the launch of XIAPEX in the European marketplace. We are very excited to see the results of our hard work in developing this clinical indication, now that it's available to more patients and physicians who can benefit from it."

BioSpecifics' strategic partner, Auxilium Pharmaceuticals, Inc. (Auxilium), markets injectable collagenase for Dupuytren's contracture in the United States under the trade name XIAFLEX®, and sub-licensed Pfizer the rights to market it for Dupuytren's contracture and Peyronie's disease in 27 member countries of the European Union and 19 other European and Eurasian countries.

Under the terms of the strategic alliance agreement between BioSpecifics and Auxilium, BioSpecifics will receive 8.5% of each additional
'/>"/>

SOURCE BioSpecifics Technologies Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BioSpecifics Technologies Corp. to Present at the Roth Capital Partners 23rd Annual OC Growth Stock Conference
2. BioSpecifics Technologies Corp. Amends Its Rights Agreement
3. BioSpecifics Technologies Corp. to Present at Lazard Capital Markets 7th Annual Healthcare Conference
4. BioSpecifics Technologies Corp. Awarded Two Qualifying Therapeutic Discovery Project Grants
5. BioSpecifics Technologies Corp. to Present at BioCentury Newsmakers in the Biotech Industry Conference
6. BioSpecifics Technologies Corp. Announces Initiation of Global Phase 3 Trial of XIAFLEX® for Treatment of Peyronies Disease
7. BioSpecifics Technologies Corp. to Host Conference Call to Report Second Quarter 2010 Financial Results on August 6, 2010
8. BioSpecifics Technologies Corp. Announces Auxilium XIAFLEX® Update
9. BioSpecifics Technologies Corp. to Present at Jefferies & Company 2010 Global Life Sciences Conference
10. BioSpecifics Technologies Corp. to Host Conference Call to Report First Quarter 2010 Financial Results on May 7, 2010
11. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... YORK , Aug. 27, 2014 ... new market research report is available ... Chinese Guidebook for Application and Approval ... Regulations to Practices (2014 Edition) ... Now, Chinese regulations ...
(Date:8/27/2014)... -- CVS Caremark (NYSE: CVS ) announced today ... MedStar Health, a leading health care system with ten ... Washington, DC , region, which will ... patients. Through this clinical affiliation, MedStar Health patients will ... chronic disease monitoring and wellness programs at CVS/pharmacy stores ...
(Date:8/27/2014)... 27, 2014 Amgen (NASDAQ: AMGN ... (FDA) has granted priority review designation for ivabradine for ... an oral drug that inhibits the I ... the body,s cardiac pacemaker. 1 Ivabradine works to ... contractility or ventricular repolarization. 1 Heart failure is ...
Breaking Medicine Technology:Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 2Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 3Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 4Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 5Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 6Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 7Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 8Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 9Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 10CVS Caremark Announces New Clinical Affiliation with MedStar Health 2CVS Caremark Announces New Clinical Affiliation with MedStar Health 3FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 2FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 3FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 4FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 5FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 6FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 7
... 18, 2007 /PRNewswire-FirstCall/ -- Vical,Incorporated today announced that ... following interim analysis of data,from the first 41 ... an,angiogenesis product candidate using Vical's DNA delivery,technology. Based ... the trial had been achieved with statistical,significance and ...
... Primary Endpoint of Improvement in Overall,Survival, WESTMINSTER, ... Inc. today announced top line results from,ENRICH, ... Efaproxyn ,(efaproxiral) plus whole brain radiation therapy ... breast cancer. The study,failed to achieve its ...
Cached Medicine Technology:Vical Licensee AnGes MG Announces Positive Results of Phase 3,Angiogenesis Trial in Japan 2Vical Licensee AnGes MG Announces Positive Results of Phase 3,Angiogenesis Trial in Japan 3Vical Licensee AnGes MG Announces Positive Results of Phase 3,Angiogenesis Trial in Japan 4Vical Licensee AnGes MG Announces Positive Results of Phase 3,Angiogenesis Trial in Japan 5Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 2Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 3Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 4Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 5Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 6
(Date:8/27/2014)... Spine Guide has built a reputation for ... spinal health. Now, the e-health site will offer new ... back pain symptoms. Spine Guide specializes in three types ... spine surgery. , Some of the most common back ... pain radiating down the leg, inability to stand up ...
(Date:8/27/2014)... Beach, Florida (PRWEB) August 28, 2014 ... Kevin Harrington, Chairman of As Seen On TV, Inc., ... as “The Millionaire Maker”. as Excelerate attendees will learn ... and will have the ability to pitch to an ... World Renowned Business Experts and Millionaire Mentors directly to ...
(Date:8/27/2014)... When it comes to the bedroom, most homeowners want ... breaking the bank in the process. Regardless of whether individuals ... for the master bedroom or simply looking for something inexpensive ... during their Labor Day mattress promotion. , This Labor ... for the home, while enjoying free delivery. Beyond bringing the ...
(Date:8/27/2014)... San Diego, CA (PRWEB) August 27, 2014 ... homeowner insurance policies will now be easier for the ... home insurance prices that are promoted in all 50 ... http://quotespros.com/homeowners-insurance.html . , The different insurers that are ... have made it possible for adults to use the ...
(Date:8/27/2014)... August 27, 2014 Locating an approximate ... consumer to present personal information before rates would be ... that life insurance quotes are distributed online using its ... term plans that an adult has access to review ... U.S. companies. The system for quotation distribution built in ...
Breaking Medicine News(10 mins):Health News:Spine Guide Offering New Overview of Surgical Options For Back Pain 2Health News:Bedding Mart, Top Mattress Store in Broken Arrow Oklahoma, Announces a Huge Labor Day Sale 2Health News:Home Insurance Prices for All 50 States Now Supplied at Consumer Insurance Portal Online 2Health News:Life Insurance Quotes for Term Policies Now Found at Insurer Website Online 2
... Aug. 8 (HealthDay News) -- The most effective treatment for ... the continuous positive airway pressure (CPAP) machine, according to a ... mask while the patient sleeps. This treatment is highly effective ... according to the review of available evidence. However, side ...
... By Amanda Gardner HealthDay Reporter , MONDAY, Aug. ... who has cardiac catheterization to diagnose heart disease is found ... But in other hospitals, relatively few are found to have ... patients may be getting unnecessary procedures, according to a study ...
... (August 8, 2011) The use of Acute Care Emergency ... significant reductions in key patient measures, such as length of ... ED overcrowding), according to a study published in the August ... Surgeons . Emergency departments are a crucial point of access ...
... Prenatal pet exposure, a mother,s delivery mode and race are ... 2, according to a Henry Ford Hospital study. In a ... researchers found that babies who have indoor prenatal pet exposure have ... IgE, between birth and age 2. IgE is linked to the ...
... -- The discovery of a gene pattern that distinguishes highly ... may help improve treatment of bone cancer in children, according ... species that develops bone cancer spontaneously with any frequency. Dogs ... human and dog forms of bone cancer are very similar, ...
... have radical surgery at university hospitals can benefit from excellent ... death rates, according to research in the August issue of ... 2,287 patients who had radical cystectomy surgery, where the bladder ... The surgery was performed at eight Canadian academic centres between ...
Cached Medicine News:Health News:CPAP Therapy Most Effective for Sleep Apnea, Experts Say 2Health News:CPAP Therapy Most Effective for Sleep Apnea, Experts Say 3Health News:Hospitals Vary Widely in Rate of Heart Procedures: Study 2Health News:Hospitals Vary Widely in Rate of Heart Procedures: Study 3Health News:Urgent assessment in emergency departments can reduce surgical decision time and overcrowding 2Health News:Prenatal pet exposure, delivery mode, race are key factors in early allergy risk 2Health News:Study of Bone Cancer in Dogs May Improve Treatment in Kids 2Health News:Improved radical surgery techniques provide positive outcomes for bladder cancer patients 2
... monoclonal antibody based colorimetric test intended ... gonorrhoeae. The test requires less than ... heating or pretreatment. The test does ... cultures. GonoGen&trade II eliminates agglutination, guesswork, ...
... GonoGen™ is a monoclonal ... for the confirmatory identification of ... not require isolated, viable or ... specimen and two minute rotation, ...
Rapid Test Kit...
... a novel device for the growth ... and Neisseria meningitidis. This product ... is easily transportable as a self-contained ... and examine the growth of organisms ...
Medicine Products: